Wichana Chamroonrat

1 Introduction Prostate cancer is ranked as the second most prevalent malignancy among males worldwide [1]. In the early stage of prostate cancer, the local treatment such as active surveillance, prostatectomy, or external beam radiation therapy (EBRT), are recommended [2]. However, as the disease progresses to distant sites, systemic treatment modalities, including hormonal therapy, chemotherapy, immunotherapy, and radioligand therapy (RLT) have become an effective treatment option [3].

1 Introduction Prostate cancer is ranked as the second most prevalent malignancy among males worldwide [1]. In the early stage of prostate cancer, the local treatment such as active surveillance, prostatectomy, or external beam radiation therapy (EBRT), are recommended [2]. However, as the disease progresses to distant sites, systemic treatment modalities, including hormonal therapy, chemotherapy, immunotherapy, and radioligand therapy (RLT) have become an effective treatment option [3].

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.